Following a full submission.
Valsartan/hydrochlorothiazide (Co-Diovan®) is accepted for use within NHS Scotland for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on valsartan monotherapy.
No increased costs are associated with this product compared with valsartan (Diovan®) alone. Angiotensin receptor blockers are an alternative to ACE inhibitors where these are not tolerated. This fixed dose combination is one of many options for the treatment of hypertension, including other angiotensin receptor blocker/diuretic combinations, many of which are less expensive.
Download detailed advice28KB (PDF)
- Medicine name:
- Valsartan/hydrochlorothiazide (Co-Diovan®)
- SMC ID:
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Date advice published
- 13 September 2004